Q1 2025 Earnings Estimate for Nevro Corp. Issued By William Blair (NYSE:NVRO)

Nevro Corp. (NYSE:NVRO - Free Report) - Research analysts at William Blair issued their Q1 2025 earnings estimates for shares of Nevro in a note issued to investors on Tuesday, May 7th. William Blair analyst B. Vazquez anticipates that the medical equipment provider will post earnings of ($0.92) per share for the quarter. The consensus estimate for Nevro's current full-year earnings is ($2.54) per share. William Blair also issued estimates for Nevro's Q4 2025 earnings at ($0.34) EPS.

Other equities research analysts also recently issued reports about the company. Citigroup decreased their price objective on Nevro from $18.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, April 3rd. Robert W. Baird lowered their price objective on shares of Nevro from $23.00 to $19.00 and set a "neutral" rating on the stock in a research report on Thursday, February 22nd. StockNews.com raised shares of Nevro from a "sell" rating to a "hold" rating in a report on Friday, March 1st. Mizuho decreased their target price on shares of Nevro from $20.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 11th. Finally, Oppenheimer cut Nevro from an "outperform" rating to a "market perform" rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $20.00.

Nevro Stock Performance

NYSE:NVRO traded up $0.36 during mid-day trading on Thursday, reaching $10.52. 586,707 shares of the stock were exchanged, compared to its average volume of 506,214. The stock has a market capitalization of $385.88 million, a P/E ratio of -4.09 and a beta of 0.96. Nevro has a 1 year low of $10.02 and a 1 year high of $28.89. The company has a 50 day simple moving average of $13.04 and a 200-day simple moving average of $16.19. The company has a quick ratio of 4.94, a current ratio of 6.37 and a debt-to-equity ratio of 0.72.

Nevro (NYSE:NVRO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.32. Nevro had a negative return on equity of 30.22% and a negative net margin of 21.69%. The company had revenue of $101.90 million for the quarter, compared to analyst estimates of $97.90 million. During the same quarter last year, the company posted ($0.98) earnings per share. The business's quarterly revenue was up 5.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC boosted its position in shares of Nevro by 46.7% during the 3rd quarter. Armistice Capital LLC now owns 3,456,000 shares of the medical equipment provider's stock worth $66,424,000 after purchasing an additional 1,100,000 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Nevro by 69.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,026 shares of the medical equipment provider's stock valued at $22,554,000 after purchasing an additional 431,136 shares during the period. UBS Group AG lifted its stake in shares of Nevro by 19,354.5% in the third quarter. UBS Group AG now owns 903,272 shares of the medical equipment provider's stock valued at $17,361,000 after purchasing an additional 898,629 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Nevro by 0.4% in the fourth quarter. Principal Financial Group Inc. now owns 720,529 shares of the medical equipment provider's stock valued at $15,506,000 after purchasing an additional 3,086 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of Nevro by 380.1% in the fourth quarter. Federated Hermes Inc. now owns 431,153 shares of the medical equipment provider's stock valued at $9,278,000 after purchasing an additional 341,343 shares during the period. Institutional investors and hedge funds own 95.52% of the company's stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.